-
Featured
Mortality in COVID-19 Does Not Appear to Be Driven by Liver Failure
Massachusetts General Hospital researchers report that elevated liver function tests are common in COVID-19, but severe liver injury is rare, and no case of liver failure or dysfunction leading to death has been attributed directly to COVID-19.
-
Featured
Patients with Decompensated Cirrhosis Need Earlier End-of-Life Planning
Regardless of transplant candidacy, patients with decompensated cirrhosis spend a substantial portion of their last 90 days of life in the hospital, are likely to receive intensive interventions at the end of life and tend to be referred late, if at all, to palliative or hospice care.
-
Featured
Early Transplantation for Alcohol-associated Hepatitis Improves Survival
According to a mathematical model, offering liver transplantation with no minimum period of sobriety before surgery (i.e., early liver transplantation) for severe alcohol-associated hepatitis provides a fourfold increase in life expectancy compared with requiring a six-month period of sobriety before listing. having characteristics similar to patients in ACCELERATE-AH trial.
-
Red Meat Consumption Increases Risk of Nonalcoholic Fatty Liver Disease in Women
In a large prospective cohort of U.S. women, Massachusetts General Hospital researchers found that a higher intake of red meat contributed to a significant, dose-dependent increased risk of developing nonalcoholic fatty liver disease, and this association was largely mediated by obesity.
-
Monitoring Novel HBV Markers Worthwhile in HBeAg-positive Patients Coinfected With HIV
In a longitudinal study, Raymond T. Chung, MD, and colleagues in the Hepatitis B (HBV) Research Network demonstrated a clear relationship between the novel biomarkers HBV RNA and HBcrAg—and by inference HBV transcription status—in HBeAg-positive but not HBeAg-negative patients with HBV–HIV coinfection.
-
Molecular Signature Predicts Progression of Early-stage Liver Fibrosis
Raymond T. Chung, MD, vice chief of the Division of Gastroenterology and director of Hepatology and the Liver Center, and colleagues defined a molecular signature that predicts progression of early-stage liver fibrosis within five years in an etiology-agnostic manner, which can inform anti-fibrotic drug development.
Liver Contributors
-
Emily D. Bethea, MD
Associate Clinical Director of Liver Transplantation, Massachusetts General Hospital
-
Jagpreet Chhatwal, PhD
Associate Director, Institute for Technology Assessment, Assistant Professor, Harvard Medical School
Recent Article
County-level COVID-19 Data Confirms Effectiveness of Workplace Closure
-
Kathleen E. Corey, MD, MPH
Director, Fatty Liver Clinic, Mass General Gastrointestinal Unit, Associate Professor of Medicine, Harvard Medical School
Recent Article
Cardiovascular Disease Independently Associated with NAFLD in People with HIV
-
Raymond T. Chung, MD
Vice Chief, Division of Gastroenterology, Director, Hepatology and Liver Center, Massachusetts General Hospital
Recent Article
Monitoring Novel HBV Markers Worthwhile in HBeAg-positive Patients Coinfected With HIV
-
Russell P. Goodman, MD, DPhil
Hepatologist, Division of Gastroenterology, Massachusetts General Hospital, Instructor in Medicine, Harvard Medical School
Recent Article
Imbalance of Electrons in the Liver May Be A Risk Factor for Many Common Diseases
Digestive Healthcare at Mass General
The Massachusetts General Hospital Digestive Healthcare Center is a collaborative practice of gastroenterologists, endoscopists, surgeons, radiologists, pathologists, hepatologists, oncologists and radiation oncologists dedicated to the prevention, diagnosis, treatment and management of digestive diseases.